Search results
Cell Line Engineering. Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
Cell Line Engineering. Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics, is investing €325 million in a new biopharmaceuticals contract manufacturing facility in Dundalk, Co. Louth.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while ...
Dec 31, 2023 · WuXi Biologics has over 12,000 employees, including more than 4000 scientists with advanced degrees and rich work experience in biologics development, manufacturing, quality control, preclinical research and registration. All members of senior management team have worked at the forefront of biologics industry with an average working experience of over 20 years in their fields of expertise ...
WuXi Biologics (香港証券取引所 株式コード: 2269.HK) は、世界中の患者様の為に、お客様がコンセプトから商業化まで一括してバイオ医薬品を研究、開発、製造出来る真のエンドツーエンド・ソリューションを提供するグローバルな受託研究開発製造機関 (CRDMO) です、日本、中国、アメリカ、ドイツ ...
Jun 5, 2024 · Cell Line Engineering. Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
